Cargando…

Real‐world outcomes among patients with EGFR‐mutated non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first‐line setting

BACKGROUND: Despite national guideline recommendations, epidermal growth factor receptor mutated (EGFRm) metastatic non‐small cell lung cancer (mNSCLC) patients may still receive suboptimal treatment in the first line (1L). This study evaluated 1L therapy initiation in relation to biomarker testing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apple, Jon, Shenolikar, Rahul, De Silva, Kevin, Sun, Ping, Spira, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315796/ https://www.ncbi.nlm.nih.gov/pubmed/37306623 http://dx.doi.org/10.1002/cam4.6052

Ejemplares similares

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
por: Xu, Jianlin, et al.
Publicado: (2016)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Real‐world treatment patterns of metastatic non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors
por: Shenolikar, Rahul, et al.
Publicado: (2022)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
por: Gandhi, Jeet, et al.
Publicado: (2009)

Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study
por: Munawar, Kiran, et al.
Publicado: (2023)

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan
por: Yang, Szu-Chun, et al.
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2016)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021)

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
por: Thomas, Rintu, et al.
Publicado: (2019)

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation
por: Huang, Aimi, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
por: Park, Sehhoon, et al.
Publicado: (2015)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
por: Zhang, Xuedi, et al.
Publicado: (2022)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
por: Arrieta, Oscar, et al.
Publicado: (2020)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_smi0uut9g49j4qf9pq3u163l0b